Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array

Proteome Science

Stephen M Hewitt³  HyungJun Cho⁴  Soo-Heang Eo⁴  David S Kwon³  Seung-Mo Hong¹  Till Braunschweig²  Joon-Yong Chung³ 

[1] Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea;Institute of Pathology, RWTH Aachen University, Aachen 52074, Germany;Tissue Array Research Program & Applied Molecular Pathology Lab., Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA;Department of Statistics, Korea University, Seoul 136-701, South Korea

关键词: Reverse-phase protein array;    Immunohistochemistry;    Colon cancer;    Formalin-fixed paraffin-embedded;    Vascular endothelial growth factor;   

Others  :  816449
DOI  :  10.1186/1477-5956-12-27

 received in 2013-11-12, accepted in 2014-05-02,  发布年份 2014

【 摘 要 】

Background

Vascular endothelial growth factor (VEGF) is a critical pro-angiogenic factor, found in a number of cancers, and a target of therapy. It is typically assessed by immunohistochemistry (IHC) in clinical research. However, IHC is not a quantitative assay and is rarely reproducible. We compared VEGF levels in colon cancer by IHC and a quantitative immunoassay on proteins isolated from formalin fixed, paraffin embedded tissues.

Results

VEGF expression was studied by means of a well-based reverse phase protein array (RPPA) and immunohistochemistry in 69 colon cancer cases, and compared with various clinicopathologic factors. Protein lysates derived from formalin fixed, paraffin embedded tissue contained measurable immunoreactive VEGF molecules. The VEGF expression level of well differentiated colon cancer was significantly higher than those with moderately and poorly differentiated carcinomas by immunohistochemistry (P = 0.04) and well-based RPPA (P = 0.04). VEGF quantification by well-based RPPA also demonstrated an association with nodal metastasis status (P = 0.05). In addition, the normalized VEGF value by well-based RPPA correlated (r = 0.283, P = 0.018). Furthermore, subgroup analysis by histologic type revealed that adenocarcinoma cases showed significant correlation (r = 0.315, P = 0.031) between well-based RPPA and IHC.

Conclusions

The well-based RPPA method is a high throughput and sensitive approach, is an excellent tool for quantification of marker proteins. Notably, this method may be helpful for more objective evaluation of protein expression in cancer patients.

【 授权许可】

   
2014 Chung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999, 6:373-378.
• [2]Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB Jr, Ellis LM: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999, 5:3364-3368.
• [3]Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
• [4]Lee JC, Chow NH, Wang ST, Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000, 36:748-753.
• [5]Perrone G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetrani A, Rabitti C: Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 2004, 208:227-234.
• [6]Cristi E, Perrone G, Toscano G, Verzi A, Nori S, Santini D, Tonini G, Vetrani A, Fabiano A, Rabitti C: Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol 2005, 58:1170-1174.
• [7]Taylor CR: The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 2000, 124:945-951.
• [8]Taylor CR, Levenson RM: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006, 49:411-424.
• [9]Takikita M, Chung JY, Hewitt SM: Tissue microarrays enabling high-throughput molecular pathology. Curr Opin Biotechnol 2007, 18:318-325.
• [10]Miyaji T, Hewitt SM, Liotta LA, Star RA: Frozen protein arrays: a new method for arraying and detecting recombinant and native tissue proteins. Proteomics 2002, 2:1489-1493.
• [11]Chung JY, Braunschweig T, Baibakov G, Galperin M, Ramesh A, Skacel M, Gannot G, Knezevic V, Hewitt SM: Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics 2006, 6:767-774.
• [12]Shi SR, Liu C, Balgley BM, Lee C, Taylor CR: Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem 2006, 54:739-743.
• [13]Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H: Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol 2007, 211:370-378.
• [14]Chung JY, Lee SJ, Ylaya K, Braunschweig T, Traicoff JL, Hewitt SM: A well-based reverse-phase protein array applicable to extract from formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl 2008, 2:1539-1547.
• [15]Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N: Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91:2026-2032.
• [16]Toi M, Matsumoto T, Bando H: Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001, 2:667-673.
• [17]Prall F, Gringmuth U, Nizze H, Barten M: Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 2003, 42:482-491.
• [18]Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
• [19]Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F: Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002, 20:184-190.
• [20]Gunsilius E, Tschmelitsch J, Eberwein M, Schwelberger H, Spizzo G, Kahler CM, Stockhammer G, Lang A, Petzer AL, Gastl G: In vivo release of vascular endothelial growth factor from colorectal carcinomas. Oncology 2002, 62:313-317.
• [21]Werther K, Christensen IJ, Nielsen HJ: A consistent shift in VEGF determinations between two different ELISA batch numbers. Br J Cancer 2003, 89:420.
• [22]Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F: Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology 2006, 71:176-184.
• [23]Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003, 97:960-968.
• [24]Zheng S, Han MY, Xiao ZX, Peng JP, Dong Q: Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003, 9:1227-1230.
• [25]Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB: The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003, 200:183-194.
• [26]Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B: Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001, 8:260-267.
• [27]Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 2005, 27:225-228.
• [28]Abdou AG, Aiad H, Asaad N, Abd El-Wahed M, Serag El-Dien M: Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma. J Egypt Natl Canc Inst 2006, 18:311-322.
• [29]Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997, 79:206-213.
• [30]Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
• [31]Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
• [32]Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA: Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008, 132:1929-1935.
• [33]Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM: Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006, 48:787-794.